- Conditions
- Sickle Cell Anemia, Pulmonary Hypertension
- Interventions
- Nitric Oxide, INO Pulse - NO Delivery System
- Drug · Device
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2015
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Sotatercept, Placebo, Background PAH Therapy
- Biological · Drug
- Lead sponsor
- Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 324 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 39
- States / cities
- Phoenix, Arizona • Tucson, Arizona • San Diego, California + 32 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Sotatercept, Background PAH Therapy
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 130 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 3
- States / cities
- Aurora, Colorado • Kansas City, Kansas • Albuquerque, New Mexico
- Conditions
- Sickle Cell Disease, Pulmonary Hypertension
- Interventions
- Hydroxyurea
- Drug
- Lead sponsor
- Ann & Robert H Lurie Children's Hospital of Chicago
- Other
- Eligibility
- 10 Years to 25 Years
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Caridovascular Disease, Congenital Heart Disease, Pulmonary Hypertension
- Interventions
- Cardiac Real-time MRI RHC (Right Heart Catheterization)
- Procedure
- Lead sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
- NIH
- Eligibility
- 2 Years to 99 Years
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2019
- U.S. locations
- 1
- States / cities
- Bethesda, Maryland
- Conditions
- Pulmonary Hypertension
- Interventions
- Pulmonary Index of Microcirculatory Resistance, Right Ventricle Index of Microcirculatory Resistance, Pulmonary artery OCT
- Other
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Pulmonary Arterial Hypertension, Pulmonary Hypertension
- Interventions
- Sitaxsentan, Sitaxsentan and Sildenafil
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 16 Years to 80 Years
- Enrollment
- 131 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 12
- States / cities
- Fountain Valley, California • Gainesville, Florida • Weston, Florida + 9 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Notapplicable
- Other
- Lead sponsor
- Actelion
- Industry
- Eligibility
- Not listed
- Enrollment
- 2,200 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 105
- States / cities
- Phoenix, Arizona • La Jolla, California • Loma Linda, California + 89 more
- Conditions
- Pulmonary Hypertension
- Interventions
- Ambrisentan
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 372 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 44
- States / cities
- Phoenix, Arizona • Los Angeles, California • Sacramento, California + 36 more
- Conditions
- Hypertension, Pulmonary
- Interventions
- Assigned pulmonary hypertension medication
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- Up to 18 Years
- Enrollment
- 2,691 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Right Heart Failure, Pulmonary Hypertension
- Interventions
- Spironolactone and conivaptan
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years to 75 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Pulmonary Hypertension, Pulmonary Arterial Hypertension
- Interventions
- 129Xe Hyperpolarized
- Drug
- Lead sponsor
- Bastiaan Driehuys
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- (-)-Epicatechin
- Drug
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Opsumit (macitentan)
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- Not listed
- Enrollment
- 2,686 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 144
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Fullerton, California + 117 more
- Conditions
- Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
- Interventions
- PRX-08066
- Drug
- Lead sponsor
- Epix Pharmaceuticals, Inc.
- Industry
- Eligibility
- 25 Years to 79 Years
- Enrollment
- 72 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2007
- U.S. locations
- 19
- States / cities
- Anniston, Alabama • Phoenix, Arizona • Sacramento, California + 14 more
- Conditions
- Pulmonary Hypertension, Metal Poison
- Interventions
- Metal level measurements
- Diagnostic Test
- Lead sponsor
- Jiapeng Huang
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 110 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2029
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Treprostinil diethanolamine
- Drug
- Lead sponsor
- United Therapeutics
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 64 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension
- Interventions
- Non-invasive hemodynamic measurements
- Device
- Lead sponsor
- University of California, Los Angeles
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Persistent Pulmonary Hypertension of the Newborn
- Interventions
- 1 dose of sildenafil
- Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- Up to 364 Days
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2016
- U.S. locations
- 9
- States / cities
- Birmingham, Alabama • Indianapolis, Indiana • Louisville, Kentucky + 6 more
- Conditions
- Hypertension;Pulmonary;Primary
- Interventions
- Not listed
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- Up to 6 Years
- Enrollment
- 43 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Hypertension, Pulmonary
- Interventions
- Selexipag, Placebo, Standard of Care (SOC): Endothelin receptor antagonist, SOC: Phosphodiesterase type 5 (PDE-5) inhibitor, SOC: Soluble guanylate cyclase stimulator
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Los Angeles, California • San Francisco, California + 10 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Selexipag, Placebo
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 108 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 15
- States / cities
- Torrance, California • Atlanta, Georgia • Louisville, Kentucky + 11 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Esuberaprost, Placebo
- Drug
- Lead sponsor
- Lung Biotechnology PBC
- Industry
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 112 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 43
- States / cities
- Birmingham, Alabama • Beverly Hills, California • La Jolla, California + 37 more
- Conditions
- Pulmonary Arterial Hypertension
- Interventions
- Pemziviptadil (PB1046)
- Drug
- Lead sponsor
- PhaseBio Pharmaceuticals Inc.
- Industry
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 26
- States / cities
- Mobile, Alabama • Tucson, Arizona • La Jolla, California + 19 more